GO
Loading...

Merck & Co Inc

More

  • BUSINESS-NEWS-SCHEDULE AT 0830 GMT / 4.30 AM ET Friday, 17 Oct 2014 | 5:02 AM ET

    LONDON- World stocks hit a nine-month low but oil and southern European bonds are off their week's lows, as investors begin to dust themselves off after one of the most volatile spells in world markets in years. LONDON- The Bank of England may need to keep interest rates lower for longer than previously thought to reduce the chance of Britain's economy slipping...

  • Can health-care stock funds stay on top? Thursday, 16 Oct 2014 | 2:53 PM ET

    NEW YORK— When swings in the stock market cause anxiety to spike, like it is now, many investors aim to get healthy. Stocks don't come with guarantees, but health care stocks have held up better than others during past downturns. People get sick regardless of the economy's strength, after all, and an aging population around the world means more demand for...

  • Ex-financial analyst facing insider trading charge Tuesday, 14 Oct 2014 | 6:46 PM ET

    NEW YORK— A former senior finance analyst at Merck& Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits. Zachary Zwerko, 32, was arrested Friday in Cambridge, Massachusetts, where he lives. Authorities said Zwerko fed secrets about plans for...

  • LONDON, Oct 14- GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of...

  • New once-a-day pill for hepatitis C wins FDA OK Friday, 10 Oct 2014 | 1:53 PM ET

    WASHINGTON— Federal health officials have approved a daily pill that can cure the most common form of hepatitis C without the grueling pill-and-injection cocktail long used to treat the virus. But the drug's $1,125- per-pill price is sure to increase criticism of drugmaker Gilead Sciences, whose pricing strategy for an older hepatitis drug has already drawn...

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...

  • Oct 7- Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country. Bristol-Myers is racing against Merck& Co and AbbVie to try and cut the treatment time by half and avoid side effects from older standard drugs interferon and ribavirin.

  • Goldman tops M&A league, tax inversion deals soar Thursday, 2 Oct 2014 | 2:57 AM ET

    Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions.

  • Cramer selloff plan: Surviving as stocks tumble Wednesday, 1 Oct 2014 | 6:08 PM ET

    The next leg of this market isn’t going to be easy. Cramer, however, has a plan.

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • NEW YORK, Sept 29- U.S. stock index futures were lower on Monday, indicating Wall Street's recent weakness would continue amid ongoing civil unrest in Hong Kong.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Stocks fall amid global concerns; small caps hit again Tuesday, 23 Sep 2014 | 4:19 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks declined Tuesday amid increased conflict in the Middle East and as the U.S. moved to curb inversion deals.

  • Your first trade for Tuesday Monday, 22 Sep 2014 | 6:01 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Early movers: SIAL, MSFT, BABA, GOOG, GM & more Monday, 22 Sep 2014 | 7:37 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.